ZDHHC9 and breast cancer: Using the CMap databases, we found that high ZDHHC9 expression in BC was associated with increased sensitivity to certain chemotherapy agents and that the tyrosine kinase inhibitor imatinib scored highest as a potential repositioned drug to counteract ZDHHC9’s oncogenic effects (Figure 11A).